![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Nishida, K Miyata, R Tsutsumi, H Yuki, S Akuzawa, A Kobayashi, T Kamato, H Ito, M Yamano and Y Katuyama
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki, Japan.
(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022) is an extremely potent and highly selective gastrin/cholecystokinin (CCK)-B receptor antagonist. We compared the gastrin/CCK-B receptor-blocking properties of this compound with those of the racemate (mixture of YM022 and its S- form), its enantiomer (S-form), L-365, 260 and Cl-988 in vitro and in vivo. YM022 replaced specific binding of [125I]CCK-8 to rat brain gastrin/CCK-B receptors in a stereoselective and competitive manner. The Ki value of YM022 for gastrin/CCK-B receptors in brain were estimated to be 0.068 nM. The racemate, the S-form of YM022, L-365,260 and Cl-988 also replaced gastrin/CCK-B receptor binding, with Ki values of 0.11, 140, 19 and 6.3 nM, respectively. The affinity of YM022 for gastrin/CCK-B receptor was more than 2 orders of magnitude higher than that for rat pancreatic CCK-A receptor and various other receptors, such as benzodiazepine. In vivo, intravenous (i.v.) administration of YM022 inhibited pentagastrin-induced gastric acid secretion in anesthetized rats, with an ED50 value of 0.0078 mumol/kg. Inhibition by the S-form of YM022 was only 33.8% even at the relatively high dose of 1 mumol/kg i.v. L-365,260 (1-10 mumol/kg i.v.) and Cl-988 (0.3-3 mumol/kg i.v.) also antagonized acid secretion induced by pentagastrin, with ED50 values of 4.23 and 1.01 mumol/kg, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  P.-Y. Deng and S. Lei Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats J. Physiol., April 15, 2006; 572(2): 425 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chao, K. L. Ives, E. Goluszko, A. A. Kolokoltsov, R. A. Davey, C. M. Townsend Jr., and M. R. Hellmich Src Regulates Constitutive Internalization and Rapid Resensitization of a Cholecystokinin 2 Receptor Splice Variant J. Biol. Chem., September 30, 2005; 280(39): 33368 - 33373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Attoub, S. Levasseur, M. Buyse, H. Goïot, J.-P. Laigneau, L. Moizo, F. Hervatin, Y. Le Marchand-Brustel, J. M. M. Lewin, and A. Bado Physiological Role of Cholecystokinin B/Gastrin Receptor in Leptin Secretion Endocrinology, October 1, 1999; 140(10): 4406 - 4410. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Bläker, Y. Ren, M. C. Gordon, J. E. Hsu, M. Beinborn, and A. S. Kopin Mutations within the Cholecystokinin-B/Gastrin Receptor Ligand `Pocket' Interconvert the Functions of Nonpeptide Agonists and Antagonists Mol. Pharmacol., November 1, 1998; 54(5): 857 - 863. [Abstract] [Full Text]
|
|
|
|
|
|
M. Beinborn, S. M. Quinn, and A. S. Kopin Minor Modifications of a Cholecystokinin-B/Gastrin Receptor Non-peptide Antagonist Confer a Broad Spectrum of Functional Properties J. Biol. Chem., June 5, 1998; 273(23): 14146 - 14151. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
